Get the Stockscreener App
294.60
2.00%
5.775
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Ligand Pharmaceuticals Inc stock is traded at $294.60, with a volume of 197.21K.
It is up +2.00% in the last 24 hours and down -2.12% over the past month.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
See More
Previous Close:
$288.82
Open:
$287.61
24h Volume:
197.21K
Relative Volume:
0.56
Market Cap:
$5.87B
Revenue:
$274.48M
Net Income/Loss:
$153.56M
P/E Ratio:
39.94
EPS:
7.3755
Net Cash Flow:
$114.06M
1W Performance:
+0.49%
1M Performance:
-2.12%
6M Performance:
+60.25%
1Y Performance:
+91.56%
1-Day Range:
$287.20
$295.19
1-Week Range:
$285.24
$299.38
52-Week Range:
$149.51
$326.63
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Name
Ligand Pharmaceuticals Inc
Sector
Industry
Phone
858-550-7500
Address
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
294.60 | 5.85B | 274.48M | 153.56M | 114.06M | 7.3755 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-26 | Initiated | BofA Securities | Buy |
| Dec-09-25 | Initiated | Citigroup | Buy |
| Apr-10-25 | Initiated | Stifel | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Resumed | Stephens | Overweight |
| Feb-04-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-06-20 | Initiated | Barclays | Overweight |
| Mar-24-20 | Downgrade | Argus | Buy → Hold |
| Mar-10-20 | Initiated | Guggenheim | Neutral |
| Feb-06-20 | Initiated | The Benchmark Company | Buy |
| Sep-19-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-03-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-06-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Oct-02-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-18 | Reiterated | Argus | Buy |
| Aug-17-18 | Initiated | Goldman | Neutral |
| Aug-08-18 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-21-18 | Initiated | Argus | Buy |
| Dec-27-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-17 | Resumed | H.C. Wainwright | Buy |
| Oct-05-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-16 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-11-16 | Initiated | Sidoti | Buy |
| Mar-03-16 | Initiated | H.C. Wainwright | Buy |
View All
Ligand Pharmaceuticals Inc Stock (LGND) Latest News
Ligand Pharmaceuticals (NASDAQ:LGND) Director Jason Haas Sells 7,138 Shares - MarketBeat
Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) CFO Sells 31,641 Shares of Stock - MarketBeat
Ligand Pharmaceuticals CFO Octavio Espinoza sells $9.2m in shares By Investing.com - Investing.com UK
Ligand Pharmaceuticals CFO Octavio Espinoza sells $9.2m in shares - Investing.com
Ligand Pharmaceuticals (LGND) director exercises options and sells 7,138 shares - Stock Titan
LGND Initiated Coverage by Leerink Partners -- Rating Outperform - GuruFocus
Ligand Pharmaceuticals (NASDAQ:LGND) Now Covered by Leerink Partners - MarketBeat
Stifel reiterates Buy on Ligand Pharma stock, $332 target By Investing.com - Investing.com Canada
Ligand Pharmaceuticals (LGND) Stock Trades Below Fair Value Following A 337% Run - Yahoo Finance
Ligand Pharmaceuticals (LGND) Reaffirms 2026 Guidance, Is The Stock Fully Priced? - Yahoo Finance
Invesco Ltd. (LGND holder) reports 6.1% beneficial stake in Ligand Pharmaceuticals - Stock Titan
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo Finance
Enterprise value to EBIT forward of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView
LIGAND PHARMACEUTICALS INC SEC Filing (Aug 12, 2026) - Stock Titan
Ligand (NASDAQ: LGND) holder Jason Haas files Form 144 for stock sale - Stock Titan
Citi Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $390 - Moomoo
Q1 2026 Ligand Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q4 2025 Ligand Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Ligand Pharmaceuticals Incorporated (LGND) stock price, news, quote and history - Yahoo Finance UK
Ligand Pharmaceuticals Incorporated (LGND) Stock Price, News, Quote & History - Yahoo! Finance Canada
LGND: XOMA Acquisition Closed - Smartkarma
Weekly Recap: Q2 revenue, royalty growth and $700M convertible notes - TradingView
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Issues Quarterly Earnings Results - MarketBeat
A Quick Look at Today's Ratings for Ligand Pharmaceuticals(LGND.US), With a Forecast Between $326 to $370 - Moomoo
California State Teachers Retirement System Acquires 4,987 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
LGND SWOT Analysis: Strong Revenue Growth Amidst Valuation Concerns Revealed in 10-Q Filing - GuruFocus
Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Announces Target Price $370 - Moomoo
RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $345 - Moomoo
Oppenheimer Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $326 - Moomoo
Ligand Pharmaceuticals (LGND) Releases Q2 2026 Earnings: Revenue Declines but EPS Jumps - quiverquant.com
LGND Maintained by RBC Capital -- Price Target Raised to $345 - GuruFocus
Ligand Pharmaceuticals 2Q 2026: Revenue $63.69M, EPS $2.22— 10-Q Summary - TradingView
Ligand Pharmaceuticals (NASDAQ: LGND) lifts Q2 net income to 48,508 - Stock Titan
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat
Ligand Pharmaceuticals, Inc. : H.c. Wainwrigh - Moomoo
RBC Adjusts PT on Ligand Pharmaceuticals to $345 From $340, Maintains Outperform Rating - marketscreener.com
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
LIGAND PHARMACEUTICALS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $358 FROM $289 - Bitget
Ligand Pharmaceuticals Inc (LGND) (Q2 2026) Earnings Call Highli - GuruFocus
Ligand Pharmaceuticals (NASDAQ:LGND) Given New $358.00 Price Target at HC Wainwright - MarketBeat
Earnings call transcript: Ligand beats Q2 2026 estimates as shares rise - Investing.com Canada
Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary - Yahoo Finance
LGND Maintained by HC Wainwright & Co. -- Price Target Raised to $358 - GuruFocus
Ligand Pharmaceuticals Q2 Earnings Call Highlights - Yahoo Finance
Enterprise value to EBIT forward of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView
Ligand Pharmaceuticals Incorporated Stock 12‑Month Price Target Raised to $343.3, Implies 13% Upside - TradingView
Ligand Pharmaceuticals Incorporated 2026 Q2ResultsEarnings Call Presentation (NASDAQ:LGND) 2026-08-06 - Seeking Alpha
Ligand Pharmaceuticals (NASDAQ:LGND) Issues FY 2026 Earnings Guidance - MarketBeat
Is Ligand Pharmaceuticals (LGND) Trading at 69.1% Overvaluation - GuruFocus
Ligand Pharmaceuticals Incorporated reports results for the quarter ended June 30Earnings Summary - TradingView
Ligand Pharmaceuticals Inc Stock (LGND) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):